Thus, the present study sought to clarify this issue by conducting a comprehensive systematic review and network meta-analysis to compare the benefits of CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments in patients with HR-positive, HER2-negative advanced breast cancer based on clinical outcomes. Here, HDAC9 is linked to breast cancer.